linagliptin + rifampicin

**Linagliptin + rifampicin** refers to the concurrent use of linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor for type 2 diabetes mellitus, and rifampicin, a broad-spectrum antibiotic primarily used for tuberculosis and other bacterial infections. Linagliptin acts by inhibiting DPP-4, thereby increasing levels of incretin hormones, which improves insulin secretion and decreases glucagon concentrations in a glucose-dependent manner. Rifampicin is a potent inducer of cytochrome P450 3A4 and P-glycoprotein, markedly affecting the pharmacokinetics of many drugs, including linagliptin. Co-administration leads to a significant reduction in plasma concentrations and efficacy of linagliptin (AUC and Cmax reduced by about 40–44%). Therefore, this particular drug combination is not recommended or is considered contraindicated due to the risk of poor glycemic control from reduced linagliptin exposure[1][2][3].

Other names

linagliptin and rifampicin